EMA issueSomeone said Paul addressed the EMA issue in today's Bloom Burton call. I didn't hear that but may have missed it. In the Q&A, a EMA question was asked but due to the bad audio, I think Paul thought the question was about the FDA and answered it (actually re-answered it might be a better description since he had already addressed the FDA meeting) as if the question was again about the FDA meeting. So, I did not hear any new insight regarding the FDA on the call. Did I miss something?